A Study to Assess Single and Multiple Doses of IkT-148009 in Healthy Elderly Participants and Parkinson's Patients
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
This study investigates the safety and tolerability of drug IkT-148009 in healthy elderly
volunteers (55 to 70 years old). It also looks at the movement of IkT-148009 in the body.
This first-in-human study is designed in 3 parts. In Part A, healthy participants will take a
single, oral dose of IkT-148009 or placebo. Part A participants will be at the study site for
approximately 4 days. In Part B, healthy participants will take an oral dose of IkT-148009
once a day for 7 days. Part B participants will be at the study site for approximately 12
days. In Part C, Parkinson's patients will take an oral dose of IkT-148009 once a day for 7
days. Part C participants will be at the study site for approximately 12 days.